Solid Organ Transplantation Rejection Market by Offering, Organ Type, Rejection Type, End-User

Description

List of Tables

[181 Pages Report] The Solid Organ Transplantation Rejection Market size was estimated at USD 7.79 billion in 2023 and expected to reach USD 8.15 billion in 2024, at a CAGR 4.90% to reach USD 10.89 billion by 2030.

Solid organ transplantation, encompassing the replacement of vital organs, including the lungs, heart, kidneys, or liver, markedly improves patient survival and quality of life. Solid organ transplantation rejection is a process in which a recipient's immune system identifies the transplanted organ as foreign and causes damage to the transplanted organ, creating the need for solid organ transplantation rejection medications and therapies. There is a rising number of individuals worldwide who suffer from organ failures, primarily due to chronic diseases, aging, and lifestyle factors. As the demand for organ transplants increases, the requirement for effective rejection management solutions also increases. This rise in organ transplantation propels the market growth. In addition, the rising public and professional awareness of advancements in solid organ transplantation and improved rejection management techniques significantly contribute to market growth. However, solid organ transplantation involves complex and costly medical procedures, including pre-transplant screenings, the surgery itself, post-operative care, and ongoing immunosuppression treatments, which require high costs and can be a significant barrier to market growth, as they may limit transplantation's accessibility for patients and strain healthcare budgets, particularly in less economically developed regions. The ongoing development of refined immunosuppressive treatments offers the opportunity for market expansion by reducing the incidence of organ rejection post-transplant.

KEY MARKET STATISTICS
Base Year [2023]	USD 7.79 billion
Estimated Year [2024]	USD 8.15 billion
Forecast Year [2030]	USD 10.89 billion
CAGR (%)	4.90%

Regional Insights

In the Americas, particularly the United States, there is a high prevalence of organ transplants due to advanced medical facilities and a well-structured healthcare system. This region has a robust organ transplantation network and showcases a significant number of transplant procedures, leading to a substantial need for anti-rejection drugs and therapies. These products are essential to help in reducing the immune response against transplanted organs. The U.S. also leads in adopting new and advanced therapies due to strong regulatory support and substantial healthcare spending. The Asia-Pacific region is showcasing growth in the solid organ transplant rejection market, propelled by increasing healthcare infrastructure, rising medical tourism due to lower treatment costs, and growing awareness about transplantation as a viable option for chronic diseases. Countries, including India and China are seeing increased numbers of transplantations. The market for solid organ transplant rejection interventions in the EMEA region showcases significant growth due to increasing organ transplant procedures and heightened awareness about transplant rejection. Europe has well-established healthcare systems and supportive regulatory frameworks. The Middle East and Africa are witnessing gradual growth, influenced by improving healthcare infrastructure and international collaborations for transplant programs.

Market Insights

Market Dynamics

The market dynamics represent an ever-changing landscape of the Solid Organ Transplantation Rejection Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

Market Drivers
- Growing number of organ transplants worldwide
- Rising awareness about the advancements in transplantation and rejection management

Market Restraints
- High costs associated with transplantation procedures

Market Opportunities
- Advancements in immunosuppressive treatments and monitoring technologies
- Emergence of genetic testing to improve predicting rejection risks accurately

Market Challenges
- Complexities associated with immunosuppressive therapies

Market Segmentation Analysis
- Offering: Increasing need for medication to treat the rejection of the transplanted organ
- End-User: Extensive use in hospitals for managing solid organ transplantation rejection

Market Disruption Analysis
Porter's Five Forces Analysis
Value Chain & Critical Path Analysis
Pricing Analysis
Technology Analysis
Patent Analysis
Trade Analysis
Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Solid Organ Transplantation Rejection Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Solid Organ Transplantation Rejection Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Pioneering Partnership Targets Breakthrough in Organ Transplant Rejection Prevention

Taiwan Bio and TRACT Therapeutics collaborated on cutting-edge cellular therapy aimed at transforming the prevention of allograft rejection in solid organ transplants. This new alliance enhanced a Phase 2 clinical trial across multiple centers in the U.S. and Taiwan, focusing on decreasing the reliance on immunosuppressant drugs in recipients of kidney transplants from living donors. Combining Taiwan Bio's expertise in cellular therapy manufacturing with TRACT Therapeutics' innovative regulatory T-cell therapy platform, this partnership aims to significantly enhance transplant outcomes while improving patients' quality of life. [Published On: 2023-12-06]

New Development in Post-Transplant Monitoring: Real-Time Electronic Organ Health Tracker

Researchers at Northwestern University innovated the first electronic device designed for continuous, real-time health monitoring of transplanted organs. This study introduces a novel, ultrathin sensor that sits atop transplanted kidneys to monitor for temperature anomalies indicative of inflammation or other complications, which could signal rejection. The device enhances patient safety by wirelessly transmitting data directly to healthcare providers via smartphone or tablet, ensuring immediate medical response to potential issues. [Published On: 2023-09-08]

GenDx Acquires Licensing for cfDNA Assay from Torino University to Enhance Lung Transplant Monitoring

GenDx, a Dutch company, has obtained exclusive licensing rights for a cell-free DNA (cfDNA) assay from Torino University. This innovative diagnostic tool is specifically designed to detect and monitor organ rejection in lung transplant recipients. The cfDNA assay offers a non-invasive method to identify early signs of rejection, which is crucial for the timely intervention and management of transplant patients. This advancement promises to enhance post-transplant care by facilitating continuous monitoring and potentially improving patient outcomes. [Published On: 2023-05-25]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Solid Organ Transplantation Rejection Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Solid Organ Transplantation Rejection Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Accord Healthcare Limited, Asahi Kasei Corporation, Astellas Pharma Inc., Biocon, Cipla Ltd., Dr. Reddy's Laboratories Ltd., Eris Lifesciences Ltd., Eurofins Transplant Diagnostics, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Globela Pharma, Lupin Limited, Manus Aktteva Biopharma LLP, Natco Pharma Ltd., Novartis AG, Panacea Biotec Pharma Ltd., Pfizer Inc., Plexision, Sanofi S.A., SAS Alsachim by Shimadzu Group, Strides Pharma Global Pte Ltd., Teva Pharmaceuticals Inc., Thermo Fisher Scientific Inc., Veloxis Pharmaceuticals A/S, and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Solid Organ Transplantation Rejection Market to forecast the revenues and analyze trends in each of the following sub-markets:

Offering
- Diagnosis & Testing Solutions
  - Biopsy
  - Blood Tests
  - Imaging Tests

Medications
- Antibodies
- Antimetabolites
- Calcineurin Inhibitors
- Steroids

Organ Type
- Heart
- Kidneys
- Liver
- Lungs
- Pancreas

Rejection Type
- Acute Rejection
- Chronic Rejection
- Hyperacute Rejection

End-User
- Hospitals
- Specialty Clinics

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam

Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom

Product Code: MRR-CB04E05661AD

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Growing number of organ transplants worldwide
  - 5.1.1.2. Rising awareness about the advancements in transplantation and rejection management
- 5.1.2. Restraints
  - 5.1.2.1. High costs associated with transplantation procedures
- 5.1.3. Opportunities
  - 5.1.3.1. Advancements in immunosuppressive treatments and monitoring technologies
  - 5.1.3.2. Emergence of genetic testing to improve predicting rejection risks accurately
- 5.1.4. Challenges
  - 5.1.4.1. Complexities associated with immunosuppressive therapies
5.2. Market Segmentation Analysis
- 5.2.1. Offering: Increasing need for medication to treat the rejection of the transplanted organ
- 5.2.2. End-User: Extensive use in hospitals for managing solid organ transplantation rejection
5.3. Market Disruption Analysis
5.4. Porter's Five Forces Analysis
- 5.4.1. Threat of New Entrants
- 5.4.2. Threat of Substitutes
- 5.4.3. Bargaining Power of Customers
- 5.4.4. Bargaining Power of Suppliers
- 5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis

6. Solid Organ Transplantation Rejection Market, by Offering

6.1. Introduction
6.2. Diagnosis & Testing Solutions
6.3. Medications

7. Solid Organ Transplantation Rejection Market, by Organ Type

7.1. Introduction
7.2. Heart
7.3. Kidneys
7.4. Liver
7.5. Lungs
7.6. Pancreas

8. Solid Organ Transplantation Rejection Market, by Rejection Type

8.1. Introduction
8.2. Acute Rejection
8.3. Chronic Rejection
8.4. Hyperacute Rejection

9. Solid Organ Transplantation Rejection Market, by End-User

9.1. Introduction
9.2. Hospitals
9.3. Specialty Clinics

10. Americas Solid Organ Transplantation Rejection Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Solid Organ Transplantation Rejection Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Solid Organ Transplantation Rejection Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
- 13.3.1. Pioneering Partnership Targets Breakthrough in Organ Transplant Rejection Prevention
- 13.3.2. New Development in Post-Transplant Monitoring: Real-Time Electronic Organ Health Tracker
- 13.3.3. GenDx Acquires Licensing for cfDNA Assay from Torino University to Enhance Lung Transplant Monitoring
13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

14.1. Key Company Profiles
14.2. Key Product Portfolio